Total Disc Replacement Versus Anterior Cervical Decompression and Fusion (CERVIDISC)

December 10, 2021 updated by: University Hospital, Bordeaux

Comparison of 2 Surgical Approaches in the Treatment of Cervical Degenerative Disc Disease: Total Disc Replacement Versus Anterior Cervical Decompression and Fusion

Background : Cervical degenerative disc disease is frequent and the consequence of aging. Degeneration may lead to disc herniation. Surgery is indicated in the presence of root compression with cervicobrachial neuralgia and/or myelopathy.

Purpose: The main objective of the study is the comparison of efficacy between total disc replacement (TDR) and Anterior Cervical Decompression and Fusion (ACDF) as surgical treatment of symptomatic cervical degenerative disc disease in term of "Success" rate, defined as preservation of adjacent segments, 24 months after surgery.

In our knowledge, there are no published data about randomized clinical trials comparing these radiological parameters (worsening of degeneration signs on static cervical spine radiographs and worsening of disc degeneration signs on MRI) at levels adjacent to surgery, between these 2 surgical approaches in patients suffering from cervical degenerative disc disease.

Study Overview

Detailed Description

Surgical treatment of cervical degenerative disc disease usually consists in neural decompression followed by intervertebral space reconstruction.

ACDF consists in interbody fusion by replacing disc space with a cage packed with bone substitute, and inserted into the anterior portion of the interspace. Fusion is successful in approximately 95% of patients with good to excellent clinical results in most of them. Unfortunately, up to 25% of these patients will develop degenerative changes at adjacent levels after surgery.

TDR consists in total disc replacement with preserved segmental motion decreasing load on adjacent levels.

Worsening of radiological degeneration signs at adjacent levels seems to be an important long term prognostic factor for reoperation.

In this trial, included patients will be randomly assigned to undergo either TDR or ACDF Six visits are planned during the study: pre inclusion visit within 3 months before surgery, inclusion/randomisation the day before surgery, 3 follow up visits (45 days, 6, and 12 months after surgery) and an end of study visit 24 months after surgery (or at time of withdrawal if relevant).

Study Type

Interventional

Enrollment (Actual)

79

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bordeaux, France, 33076
        • Chirurgie Orthopedique
      • Nice, France, 06000
        • CHU Nice - Unité de Chirurgie Rachidienne
      • Paris, France, 75013
        • Chirurgie Orthopedique

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Aged 18-60 years
  • suffering from cervical disc degenerative disease (whatever the grade, level and intervertebral disc height) needing one-level surgical treatment due to either invalidating cervicobrachial nevralgia despite 3-month optimal medical treatment or neurological symptoms, with motion of surgical level at least equal to 2° degrees, and non-degenerative adjacent discs.
  • Being affiliated to health insurance
  • Having signed an informed consent (later than the day of inclusion and before any examination required by research)

Exclusion Criteria:

  • Previous cervical traumatism and/or cervical surgery.
  • Cervical degeneration defined as a Grade 4 according to modified Mehren classification and/or a Grade 5 according to Miyazaki et al classification on T2 magnetic resonance imaging (MRI), at symptomatic level and/or its adjacent levels.
  • Myelopathy.
  • Cervical spine instability.
  • Presence of at least one major contraindication to surgery and/or general anaesthesia (ie, non-controlled coagulopathy, active infection, or serious underlying disease, auto-immune affection).
  • Presence of at least one contraindication to either TDR or ACDF procedure.
  • Presence of at least one contraindication to either static/dynamic radiographs or Magnetic Resonance Imaging (MRI).
  • Severe radiological osteoporosis.
  • Bone metabolic disease.
  • Active cancer at time of inclusion into the study.
  • Chronic intake of corticosteroids or any other treatment susceptible to interfere with study conduct and/or assessment (ie, immunosuppressive drugs).
  • Unlikely to comply with the requirements of the study and/or to complete the study for psychological, social, familial or geographical reasons.
  • No contraception for women of childbearing age
  • Pregnant or breastfeeding women
  • Being under guardianship or legal supervision.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Total disc replacement (TDR)
Total disc replacement with preserved segmental motion decreasing load on adjacent levels.
Experimental: Anterior Cervical Decompression and Fusion (ACDF)
Interbody fusion by replacing disc space with a cage packed with bone substitute, and inserted into the anterior portion of the interspace.
Axelle®

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
To compare efficacy of TDR and ACDF as surgical treatment of cervical degenerative disc disease in term of "success rate" defined as absence of radiological degenerative disease at adjacent levels
Time Frame: 24 months after surgery
24 months after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Between-group comparison of tolerance
Time Frame: 24 months after surgery

This measure is a composite with :

  • Per- and post-operative surgery parameters
  • Major complication rate
  • Minor complication rate
24 months after surgery
Between-group comparison of efficacy
Time Frame: 45 days, 6, 12 and 24 months after surgery

This measure is a composite with :

  • Cervical and radicular pain outcome as compared to preoperative status.
  • Functional outcome: Neck Disability Index (NDI) and modified Prolo Economic and Functional scores as compared to preoperative status.
  • Cervical radiological parameters
  • Quality of life outcome as compared to preoperative status.
45 days, 6, 12 and 24 months after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Olivier GILLE, Prof, University Hospital Bordeaux, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 4, 2015

Primary Completion (Actual)

November 24, 2021

Study Completion (Actual)

November 24, 2021

Study Registration Dates

First Submitted

January 28, 2015

First Submitted That Met QC Criteria

April 14, 2015

First Posted (Estimate)

April 15, 2015

Study Record Updates

Last Update Posted (Actual)

January 3, 2022

Last Update Submitted That Met QC Criteria

December 10, 2021

Last Verified

December 1, 2021

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cervical Degenerative Disc Disease

Clinical Trials on Surgical treatment of cervical degenerative disc disease (CP ESP®)

3
Subscribe